Novartis beats Q4 earnings consensus as drug sales surge
FRANKFURT (Reuters) -Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts. Fourth-quarter net income, adjusted for special items, rose 26% to $3.93 billion, the Swiss drugmaker said in a statement, surpassing an analyst consensus of $3.64 billion, according to LSEG data. Novartis shares jumped 3.6% to a three-month high of 97.15 francs at 0941 GMT, with investors also encouraged by the company's upbeat 2025 earnings projections.